SecBot SecBot
8-K ·Filed Nov 2, 2026

BMRN

BIOMARIN PHARMACEUTICAL INC
BEARISH
Impact 6/10
Horizonweeks Processed14d 6h ago SEC0001048477-26-000021
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The massive Non-GAAP EPS guidance cut (from ~$5.00 to ~$2.95) overshadows the 32% revenue beat. The shift of a large VOXZOGO international order from Q3 to Q4 and the order timing uncertainty cited in the guidance revision suggest lumpy demand patterns. Watch Q4 2026 results for recovery of that deferred order and any further guidance adjustments.

DirectionBearish
Confidencehigh
Horizonweeks

Drugs in focus

BMRN drug pipeline →

BMN 333

● Neutral Named in this 8-K
Impact
Phase
Phase 2/3
Time to market
If successful through Phase 2/3, potential launch is estimated around 2030 per earlier BioMarin guidance, though the timeline depends on Phase 2/3 results and regulatory interactions.
Next catalyst
None dated

What to watchThe next catalyst for BMN 333 is dose-response data from the Phase 2/3 dose-finding segment, expected in 2027 (no specific date given). Positive data would validate a weekly, potentially superior alternative to Voxzogo and strengthen BioMarin's achondroplasia franchise against Ascendis' newly approved Yuviwel. Negative or underwhelming data would raise doubts about the drug's best-in-class potential and could pressure BMRN shares given the competitive threat.

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$55.66
T+0 close · Nov 2, 2026 · via day close
Latest settled
+2.64%
T+5 · $57.13 · next T+20 in 15d
Vs SPY
+3.23%
α at T+5
Latest observation
+3.59%
T+8 · FF3 residual α
  1. T+0 · Nov 3 $55.66entry
  2. T+1 · 13d ago +2.64%α +0.99% · $57.13
  3. T+5 · 7d ago +2.64%α +3.23% · $57.13
  4. T+9 · todayOpen
  5. T+20 · in 15d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BioMarin reported Q3 2026 total revenues of $1.025B, up 32% YoY, driven by the Amicus acquisition (GALAFOLD and POMBILITI+OPFOLDA) and 12% VOXZOGO growth. GAAP EPS was -$0.63 (vs consensus -$0.11), heavily impacted by $288M in acquired IPR&D charges and $99M in intangible amortization. Non-GAAP EPS was $0.23. Full-year 2026 revenue guidance was lowered to $3.80B-$3.90B (from $3.875B-$3.925B) due to order timing uncertainty, and Non-GAAP EPS guidance was slashed to $2.80-$3.10 (from $4.90-$5.10) reflecting the Alesta acquisition and BMN 450 license charges.

Key Financial Metrics

EPS (Adj.)
−$0.11
est −$0.11 · 0.0% · GAAP: $-0.63
Revenue
$1.0B
est $1.0B · +0.5% · +32.0% YoY
Rating
in line
Guidance
$3.80B-$3.90B
lowered

Key Facts

  • Q3 2026 total revenues $1.025B, +32% YoY (from $776M)
  • GAAP net loss -$123M vs -$31M YoY; GAAP diluted EPS -$0.63 vs -$0.16 YoY
  • Non-GAAP income $45M vs $22M YoY; Non-GAAP diluted EPS $0.23 vs $0.12 YoY
  • Full-year 2026 revenue guidance lowered to $3.80B-$3.90B (from $3.875B-$3.925B)
  • Full-year 2026 Non-GAAP EPS guidance lowered to $2.80-$3.10 (from $4.90-$5.10), a ~40% cut at midpoint
  • Acquired IPR&D charges of $288M in Q3 2026, primarily from Alesta acquisition
  • VOXZOGO revenue $245M, +12% YoY; a large international order shifted from Q3 to Q4
  • Metabolic Conditions revenue $744M, +44% YoY, driven by GALAFOLD ($152M) and POMBILITI+OPFOLDA ($49M)
  • GAAP operating margin -8.0% vs -6.0% YoY; Non-GAAP operating margin 13.4% vs 2.8% YoY
  • PDUFA target action date of May 30, 2027 for VOXZOGO in hypochondroplasia

Financial Impact

Full-year Non-GAAP EPS guidance cut by ~40% from $5.00 midpoint to $2.95 midpoint, driven by $320M in Alesta-related pre-tax charges and $83M in BMN 450 license charges. Revenue guidance reduced by $50M at midpoint due to order timing uncertainty.

revenueepsoperating incomeguidance

Segment Breakdown

SegmentRevenueGrowth
VOXZOGO$245.0M+12.0%
Metabolic Conditions$744.0M+44.0%
KUVAN$23.0M-4.0%
ROCTAVIAN$1.0M-67.0%

Risk Factors

  • Full-year Non-GAAP EPS guidance cut by ~40% due to acquisition-related charges and order timing uncertainty
  • GAAP net loss widened to -$123M from -$31M, driven by $288M in IPR&D charges and $99M in intangible amortization
  • Revenue guidance lowered by $50M at midpoint due to uncertainty in timing of multiple orders from a single international customer
  • Large VOXZOGO international order shifted from Q3 to Q4, creating quarterly volatility
  • Integration risks from Amicus and Alesta acquisitions; ongoing restructuring costs

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
77% bullish (35 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001048477-26-000021
Document: bmrn-20261102.htm0001048477-26-000021
Document: 0001048477-26-000021-index-headers.html0001048477-26-000021
Document: 0001048477-26-000021-index.html0001048477-26-000021
Document: 0001048477-26-000021.txt0001048477-26-000021
8-K Data (Synthetic)0001048477-26-000021

Track record

16 reports on BMRN

Performance horizon

2 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +8.91% at T+60 after the Apr 27, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 4, 202612d ago SC 13G/A Neutral 3/10 Entry $56.12 to $56.70 Now $57.99 +3.33% ▲ +1.03% −2.26% vs SPY
  2. Nov 2, 202614d ago 8-K Bearish 6/10 Viewing Entry $55.66 to $57.13 Now $57.99 −4.19% ▼ −2.64% −3.23% vs SPY
  3. Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $57.49 to $56.12 Now $57.99 +0.87% ▼ −2.38% +2.34% vs SPY
  4. Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $56.00 to $57.13 Now $57.99 +3.55% ▲ +2.02% +2.73% vs SPY
  5. Oct 6, 20265w ago 8-K Bearish 6/10 Entry $55.20 to $55.14 Now $57.99 −5.05% ▲ +0.11% −0.87% vs SPY
  6. Sep 15, 20268w ago 8-K Neutral 4/10 Entry $64.45 to $63.94 Now $57.99 −10.02% ▼ −0.79% −1.61% vs SPY
  7. Sep 14, 20269w ago 8-K Neutral 2/10 Entry $66.41 to $64.06 Now $57.99 −12.68% ▼ −3.54% −3.65% vs SPY
  8. Sep 1, 202610w ago 8-K Neutral 3/10 Entry $64.84 to $64.41 Now $57.99 −10.56% ▼ −0.66% −0.74% vs SPY
  9. Sep 1, 202610w ago Press Release Neutral 4/10 Entry $64.84 to $64.41 Now $57.99 −10.56% ▼ −0.66% −0.74% vs SPY
  10. Aug 31, 202611w ago 8-K Bullish 6/10 Entry $65.23 to $64.63 Now $57.99 −11.10% ▼ −0.92% −0.78% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens Wed (10h 23m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 2, 2026